Reiko Sakurai1,2, Cindy Lee1,2, Humphrey Shen1,2, Alan J Waring1,2, Frans J Walther1,2, Virender K Rehan1,2. 1. Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Torrance, California, USA. 2. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Abstract
BACKGROUND: Despite improvements in perinatal care, bronchopulmonary dysplasia (BPD) in extremely premature infants has not decreased. Postnatal surfactant therapy provides symptomatic relief from respiratory distress syndrome, but does not translate into a reduction in BPD. Therefore, the search for effective interventions to prevent BPD continues. OBJECTIVES: Since PPAR-γ agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-γ agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone. METHODS: One-day-old Sprague-Dawley rat pups were administered PGZ + B-YL via nebulization every 24 h for up to 72 h. The pups were exposed to either 21 or 95% O2, and then sacrificed. Their lungs were examined for markers of lung maturation (levels of PPAR-γ, SP-C and choline-phosphate cytidylyltransferase [CCT-α] and [3H]triolein uptake) and injury repair (bronchoalveolar lavage cell count and protein content, and levels of LEF-1, fibronectin, ALK5, and β-catenin) by Western blot analysis. RESULTS: Markers of alveolar epithelial/mesenchymal maturation (PPAR-γ, SP-C, CCT-α, and triolein uptake) increased significantly in the PGZ + B-YL group, more than with either drug alone. Similarly, markers of hyperoxia-induced lung injury were blocked effectively with PGZ + B-YL treatment. CONCLUSIONS: Nebulized PPAR-γ agonist PGZ with a synthetic lung surfactant accelerates lung maturation and prevents neonatal hyperoxia-induced lung injury more than either modality alone, with the potential to provide more effective prevention of BPD.
BACKGROUND: Despite improvements in perinatal care, bronchopulmonary dysplasia (BPD) in extremely premature infants has not decreased. Postnatal surfactant therapy provides symptomatic relief from respiratory distress syndrome, but does not translate into a reduction in BPD. Therefore, the search for effective interventions to prevent BPD continues. OBJECTIVES: Since PPAR-γ agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-γ agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone. METHODS: One-day-old Sprague-Dawley rat pups were administered PGZ + B-YL via nebulization every 24 h for up to 72 h. The pups were exposed to either 21 or 95% O2, and then sacrificed. Their lungs were examined for markers of lung maturation (levels of PPAR-γ, SP-C and choline-phosphate cytidylyltransferase [CCT-α] and [3H]triolein uptake) and injury repair (bronchoalveolar lavage cell count and protein content, and levels of LEF-1, fibronectin, ALK5, and β-catenin) by Western blot analysis. RESULTS: Markers of alveolar epithelial/mesenchymal maturation (PPAR-γ, SP-C, CCT-α, and triolein uptake) increased significantly in the PGZ + B-YL group, more than with either drug alone. Similarly, markers of hyperoxia-induced lung injury were blocked effectively with PGZ + B-YL treatment. CONCLUSIONS: Nebulized PPAR-γ agonist PGZ with a synthetic lung surfactant accelerates lung maturation and prevents neonatal hyperoxia-induced lung injury more than either modality alone, with the potential to provide more effective prevention of BPD.
Authors: Neil N Finer; T Allen Merritt; Graham Bernstein; Leela Job; Jan Mazela; Robert Segal Journal: J Aerosol Med Pulm Drug Deliv Date: 2010-10 Impact factor: 2.849
Authors: Jean C Dubus; Laurent Vecellio; Michele De Monte; James B Fink; Daniel Grimbert; Jerome Montharu; Chantal Valat; Neil Behan; Patrice Diot Journal: Pediatr Res Date: 2005-03-17 Impact factor: 3.756
Authors: Ying Wang; Jamie Santos; Reiko Sakurai; Eugene Shin; Laura Cerny; John S Torday; Virender K Rehan Journal: Pediatr Res Date: 2009-02 Impact factor: 3.756
Authors: R Sakurai; P Villarreal; S Husain; Jie Liu; T Sakurai; E Tou; J S Torday; V K Rehan Journal: Am J Physiol Lung Cell Mol Physiol Date: 2013-06-28 Impact factor: 5.464
Authors: Frans J Walther; Alan J Waring; Jose M Hernandez-Juviel; Larry M Gordon; Adrian L Schwan; Chun-Ling Jung; Yusuo Chang; Zhengdong Wang; Robert H Notter Journal: PLoS One Date: 2007-10-17 Impact factor: 3.240